Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET
Clinical trial NCT02544633 · COMPLETED
Trial details
- NCT number
- NCT02544633
- Sponsor
- Mirati Therapeutics Inc.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2015-10-01
- Primary completion
- 2018-04-30
- Enrollment
- 68
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.